Cell Death and Disease (Jun 2024)

MicroRNA miR-20a-5p targets CYCS to inhibit apoptosis in hepatocellular carcinoma

  • Olaniyi Olarewaju,
  • Yuhai Hu,
  • Hsin-Chieh Tsay,
  • Qinggong Yuan,
  • Simon Eimterbäumer,
  • Yu Xie,
  • Renyi Qin,
  • Michael Ott,
  • Amar Deep Sharma,
  • Asha Balakrishnan

DOI
https://doi.org/10.1038/s41419-024-06841-0
Journal volume & issue
Vol. 15, no. 6
pp. 1 – 16

Abstract

Read online

Abstract Hepatocellular carcinoma is a primary liver cancer, characterised by diverse etiology, late diagnoses, and poor prognosis. Hepatocellular carcinoma is mostly resistant to current treatment options, therefore, identification of more effective druggable therapeutic targets is needed. We found microRNA miR-20a-5p is upregulated during mouse liver tumor progression and in human hepatocellular carcinoma patients. In this study, we elucidated the therapeutic potential of targeting oncogenic miR-20a-5p, in vivo, in a xenograft model and in two transgenic hepatocellular carcinoma mouse models via adeno-associated virus-mediated miR-20a-Tough-Decoy treatment. In vivo knockdown of miR-20a-5p attenuates tumor burden and prolongs survival in the two independent hepatocellular carcinoma mouse models. We identified and validated cytochrome c as a novel target of miR-20a-5p. Cytochrome c plays a key role in initiation of the apoptotic cascade and in the electron transport chain. We show for the first time, that miR-20a modulation affects both these key functions of cytochrome c during HCC development. Our study thus demonstrates the promising ‘two birds with one stone’ approach of therapeutic in vivo targeting of an oncogenic miRNA, whereby more than one key deregulated cellular process is affected, and unequivocally leads to more effective attenuation of HCC progression and significantly longer overall survival.